Bachem Holding AG is a Switzerland‐based specialty biochemical company focused on the development, manufacturing and commercialization of peptides and oligonucleotides. Serving pharmaceutical and biotechnology clients as well as academic research institutions, the company offers a broad spectrum of products ranging from custom peptide synthesis for research applications to clinical and commercial‐grade active pharmaceutical ingredients (APIs). Bachem’s expertise extends to process development, scale‐up and GMP‐compliant production, supporting projects in therapeutic areas such as oncology, metabolic disorders and infectious diseases.
Founded in 1971 and headquartered in Bubendorf, Switzerland, Bachem has grown through strategic investments in production capacity and the acquisition of complementary peptide and oligonucleotide technologies. The company operates multiple manufacturing sites across Europe, North America and Asia, including facilities in Germany, the United States and Japan. These locations are equipped with quality management systems that adhere to international regulatory standards, ensuring consistent supply and traceability for both small‐scale clinical batches and large‐volume commercial orders.
Bachem’s product portfolio encompasses catalog peptides for research use, custom synthesis services, gel‐phase and solution‐phase peptide synthesis platforms, and a range of oligonucleotide chemistries. The company places a strong emphasis on innovation, collaborating with contract research organizations, universities and pharmaceutical partners to advance new therapeutic modalities. With a global network of technical and commercial teams, Bachem provides end‐to‐end project support, from early discovery through late‐stage development and commercialization.
AI Generated. May Contain Errors.
